Everand Logo

Welcome to Everand!

  • STAT

    Listen: The future of CAR-T, an alarming cancer trend, and Sarepta’s FDA legacy

    Has CAR-T lost its luster? Why is colorectal cancer on the rise? And did the FDA forever change in 2016? Find out on the latest episode of "The Readout LOUD"…
    by Damian Garde and Rebecca Robbins and Adam Feuerstein Dec 12, 2019 1 minute

    Has CAR-T lost its luster? Why is colorectal cancer on the rise? And did the FDA forever change in 2016?

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
    Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
    Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

    Related Books & Audiobooks